What are the recommended diagnostic work‑up and first‑line treatment regimens for a newly diagnosed patient with lymphoma, including classical Hodgkin lymphoma and diffuse large B‑cell non‑Hodgkin lymphoma?

Lymphoma: Diagnostic Work-up and First-Line Treatment

For newly diagnosed classical Hodgkin lymphoma, use ABVD chemotherapy (2-4 cycles for limited-stage, 6-8 cycles for advanced-stage) combined with involved-site radiotherapy; for diffuse large B-cell lymphoma, use R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone) for 6-8 cycles every 21 days.

Diagnostic Work-up

Classical Hodgkin Lymphoma

The diagnostic approach requires an excisional lymph node biopsy as the gold standard, though core needle biopsy is acceptable if diagnostic 1, 2, 3. Fine-needle aspiration alone is insufficient except when combined with immunohistochemistry and reviewed by an expert hematopathologist 3.

Essential immunostaining panel includes:

• CD3, CD15, CD20, CD30, CD45, CD79a, and PAX5
• Reed-Sternberg cells characteristically express CD30 (all cases) and CD15 (most cases)
• Usually negative for CD3 and CD45
• CD20 detectable in <40% of cases 3

Required staging investigations:

• Complete blood count with differential, platelets, ESR
• LDH, albumin, liver and renal function tests
• PET/CT scan (skull base to mid-thigh) - essential for initial staging 1, 2, 3
• Contrast-enhanced CT of neck, chest, abdomen, pelvis
• Hepatitis B, C, and HIV screening 1
• ECG and echocardiography (baseline cardiac assessment before anthracyclines)
• Pulmonary function tests
• Reproductive counseling and pregnancy testing in younger patients 1

Diffuse Large B-Cell Lymphoma

Histological verification requires:

• Excisional biopsy or adequate core biopsy 4, 5
• Immunohistochemistry must include B-cell and T-cell markers, particularly CD20 status (critical for rituximab eligibility) 4, 5
• WHO classification diagnosis mandatory 5

Staging work-up includes:

• CT scan of chest and abdomen minimum
• Bone marrow aspirate and biopsy 5
• Diagnostic lumbar puncture with prophylactic intrathecal chemotherapy (cytarabine or methotrexate) for high-risk patients: those with >2 adverse IPI parameters, especially with bone marrow, testicular, spinal, or skull base involvement 5
• Complete blood count, LDH, uric acid
• HIV, hepatitis B and C screening
• Protein electrophoresis 4
• Ann Arbor staging with bulky disease notation 5
• International Prognostic Index (IPI) calculation for risk stratification 4, 5

First-Line Treatment Regimens

Classical Hodgkin Lymphoma

Limited-Stage Disease (Stage I-II)

Standard approach: 2 cycles of ABVD followed by 20 Gy involved-site radiotherapy (ISRT) 1, 2

The ABVD regimen consists of 1, 2:

• Doxorubicin 25 mg/m² IV on days 1 and 15
• Bleomycin 10 mg/m² IV on days 1 and 15
• Vinblastine 6 mg/m² IV on days 1 and 15
• Dacarbazine 375 mg/m² IV on days 1 and 15
• Recycle day 29

PET-guided approach (alternative):

• After 2 cycles ABVD, perform interim PET-CT
• If PET-negative (Deauville score ≤2): 1 additional ABVD cycle + 20 Gy ISRT
• If PET-positive (Deauville score ≥3): 2 cycles BEACOPPescalated + 30 Gy ISRT 2

Critical caveat: While PET-negative patients may be offered chemotherapy alone to avoid radiotherapy late effects, this approach shows inferior progression-free survival compared to combined-modality treatment 2. Radiotherapy omission should only be considered when late toxicity risks clearly outweigh benefits in individual patients.

Advanced-Stage Disease (Stage III-IV)

For patients ≤60 years:

• Standard: 6-8 cycles of ABVD 1, 6
• Alternative: 6 cycles BEACOPPescalated (superior tumor control but significantly higher acute toxicity) 1

BEACOPPescalated regimen 1:

• Bleomycin 10 mg/m² IV day 8
• Etoposide 200 mg/m² IV days 1-3
• Doxorubicin 35 mg/m² IV day 1
• Cyclophosphamide 1250 mg/m² IV day 1
• Vincristine 1.4 mg/m² IV day 8 (maximum 2 mg)
• Procarbazine 100 mg/m² PO days 1-7
• Prednisone 40 mg/m² PO days 1-14
• G-CSF from day 8
• Recycle day 22

Network meta-analysis shows BEACOPPescalated provides 10% survival advantage at 5 years compared to ABVD 1, but requires appropriate surveillance and supportive care infrastructure. ABVD remains standard for most centers given comparable overall survival in many trials and significantly better tolerability 6.

For patients >60 years:

• ABVD only - BEACOPPescalated contraindicated due to increased treatment-related mortality 1

Radiotherapy in advanced disease:

• Limited to PET-positive residual masses >2.5 cm after BEACOPPescalated 1
• Or residual masses >1.5 cm after ABVD 1

Diffuse Large B-Cell Lymphoma

All Stages (CD20-positive)

Standard first-line: R-CHOP for 6-8 cycles every 21 days 4, 5, 7

The R-CHOP regimen consists of:

• Rituximab 375 mg/m² IV day 1
• Cyclophosphamide 750 mg/m² IV day 1
• Doxorubicin 50 mg/m² IV day 1
• Vincristine 1.4 mg/m² IV day 1 (maximum 2 mg)
• Prednisone 100 mg PO days 1-5
• Recycle day 21

Alternative dosing: R-CHOP-14 (every 14 days with G-CSF support) - 6 cycles CHOP with 8 cycles rituximab is sufficient with this schedule 4

Key treatment principles:

• Avoid dose reductions for hematologic toxicity - use G-CSF prophylactically for febrile neutropenia instead 4, 5
• Tumor lysis syndrome prophylaxis mandatory in high tumor burden cases 4, 5
• Consolidation radiotherapy to bulky sites has NOT proven benefit in the rituximab era 4, 5

Risk-Stratified Approaches

Young low-risk patients (age-adjusted IPI ≤1):

• 6-8 cycles R-CHOP every 21 days 4

Young high-risk patients (age-adjusted IPI >2):

• R-CHOP remains standard 4
• Dose-intensive regimens (R-ACVBP) may be considered but remain somewhat experimental 4
• High-dose chemotherapy with autologous stem cell transplant as first-line consolidation shows promise in phase II trials but remains investigational 4

Elderly patients (60-80 years):

• 8 cycles R-CHOP-21 or 6 cycles R-CHOP-14 with 8 rituximab doses 4
• Radiotherapy consolidation provides no benefit in this age group 4

Patients >80 years:

• R-CHOP can be used in fit patients
• Rituximab with attenuated chemotherapy is an alternative for frail patients 4

CNS Prophylaxis

Mandatory for:

• High-intermediate and high-risk IPI patients

• 1 extranodal site with elevated LDH

• Testicular lymphoma (always) 4

Consider for:

• Paranasal sinus involvement
• Upper neck involvement
• Bone marrow involvement 4

Important limitation: Intrathecal methotrexate alone is probably suboptimal; systemic high-dose methotrexate-based approaches are preferred when feasible 4.

Special Extranodal Sites

Primary CNS DLBCL:

• Requires high-dose methotrexate-based regimen
• Addition of high-dose cytarabine improves complete remission rates
• CNS irradiation typically included 4

Primary testicular DLBCL:

• Standard R-CHOP plus mandatory CNS prophylaxis
• Prophylactic contralateral testicular irradiation should be considered in localized disease 4

Primary mediastinal large B-cell lymphoma:

• R-CHOP-21 not definitively established as optimal
• Radiotherapy role remains controversial 4

Response Evaluation

Timing of assessments:

• After 2-4 cycles of chemotherapy (interim)
• After completion of all therapy 1, 4, 5

Hodgkin lymphoma:

• PET/CT is essential for evaluating residual masses 2, 3
• Interim PET (after 2 cycles) predicts treatment failure and guides intensification 1, 2

DLBCL:

• Repeat abnormal baseline imaging after 3-4 cycles and at end of treatment 4, 5
• PET scanning predictive of response but routine surveillance PET not recommended 4
• Repeat bone marrow biopsy only if initially positive 5

Common Pitfalls

1. Using fine-needle aspiration alone - insufficient for diagnosis except in rare circumstances with expert cytopathology 3

2. Omitting cardiac assessment before anthracyclines - baseline echocardiography or MUGA scan essential, particularly important for cumulative dose monitoring 1

3. Forgetting CNS prophylaxis in high-risk DLBCL - particularly critical for testicular lymphoma where it is mandatory 4

4. Routine dose reductions for cytopenias - use G-CSF support instead to maintain dose intensity, which impacts cure rates 4, 5

5. Using BEACOPPescalated in patients >60 years - associated with unacceptable treatment-related mortality 1

6. Adding consolidation radiotherapy routinely in DLBCL - no proven benefit in the rituximab era for patients achieving complete remission 4, 5

7. Inadequate tumor lysis syndrome prophylaxis - essential in high tumor burden cases before starting treatment 4, 5